Sign In
Buy AXSM
$212.17
+1.13 (+0.535%)
At Close: Aug 04, 2026
These Up-and-Coming Stocks Are Screaming Buys Right Now
05:30am, Thursday, 13'th Apr 2023
Axsome launched its first products last year -- and others may be on the horizon. CRISPR recently completed regulatory submissions for a blood disorder candidate with blockbuster potential.
Can Axsome Hold Out Till Depression Drug Becomes a Blockbuster?
08:35am, Wednesday, 12'th Apr 2023
Auvelity, a drug newly approved for major depressive disorder, could exceed $1 billion in sales by 2029. Analysts still expect Axsome to lose money through 2023 as its ambitious and extensive drug dev
A New Nasdaq Bull Market Is Nearly Here: 3 Stocks to Buy Sooner Rather Than Later
05:52am, Saturday, 08'th Apr 2023
Axsome Therapeutics has multiple catalysts on the way. MercadoLibre is already in a bull market of its own and has tremendous growth opportunities in Latin America.
Has Axsome Therapeutics Become a No-Brainer Buy?
09:45am, Wednesday, 05'th Apr 2023
Axsome's revenue topped $50 million last year as Sunosi and Auvelity gave the biotech some momentum. The company believes its cash position will sustain it until the business is generating positive ca
Why Agenus, Amarin, and Axsome Therapeutics Shares Slumped Today
03:53pm, Tuesday, 04'th Apr 2023
Two economic reports point to a possible recession later this year. Investors sold off risky biotech stocks as a result.
3 Surprisingly Underrated Stocks to Buy in April
06:14am, Saturday, 01'st Apr 2023
Axsome Therapeutics has multiple catalysts on the way. Johnson & Johnson is a bargain with its improving growth prospects.
The 3 Best Growth Stocks to Buy in the Biotech Sector
10:23pm, Wednesday, 29'th Mar 2023
Investors may want to keep an eye on biotech growth stocks, which are typically associated with the risk-on trade. Case in point: The sector ran up in January, but when the broader-market rally fizzle
3 Up-and-Coming Growth Stocks to Buy Right Now
06:00am, Saturday, 25'th Mar 2023
Axsome already has two approved drugs and could add two more in the near future. Sarepta has significant growth opportunities with its rare-disease drugs.
Axsome (AXSM) Stock Up 17% in Six Months: Here's Why
01:46pm, Monday, 20'th Mar 2023
Axsome's (AXSM) shares have surged 17.2% in the past six months, owing to the launch of its first product, Auvelity, in October last year. Also, the addition of Sunosi boosts its top line.
3 Nasdaq Stocks on Watch This Week
04:45pm, Sunday, 12'th Mar 2023
Market volatility seems to be the central theme for stocks heading into next week. These three Nasdaq-listed stocks may be among the most volatile.
Axsome Therapeutics: SYMPHONY Catalyst Unlocking
02:52pm, Thursday, 09'th Mar 2023
Given that Axsome Therapeutics, Inc. is launching Auvelity with a small in-house team, you can expect a substantial sales increase in the next three years. In a highly favorable deal, Axsome recently
These Are the Top 10 Holdings of David Kim
10:55pm, Monday, 06'th Mar 2023
David Kim is the founder and Chief Investment Officer of Ghost Tree Capital. Before founding Ghost Tree Capital in 2013, Kim worked as the portfolio manager at Diamondback Capital (Nov 2006 – Dec 20
Is Axsome Therapeutics Stock a Buy Now?
06:15am, Monday, 06'th Mar 2023
Axsome Therapeutics' current portfolio could generate over $3 billion in peak annual sales. However, that won't happen for several years.
Axsome (AXSM) Q4 Earnings Miss, Auvelity Records First Sales
03:49pm, Tuesday, 28'th Feb 2023
Axsome Therapeutics (AXSM) incurs wider-than-expected loss in Q4 2022. Revenues beat estimates while shares gain.
Axsome Therapeutics (AXSM) Reports Q4 Loss, Tops Revenue Estimates
09:47am, Monday, 27'th Feb 2023
Axsome (AXSM) delivered earnings and revenue surprises of -8.47% and 13.29%, respectively, for the quarter ended December 2022. Do the numbers hold clues to what lies ahead for the stock?
